UroGen Pharma has completed the enrolment of subjects in its Phase III UTOPIA trial, which is evaluating UGN-103 for intravesical solution.

Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.

Jasper Therapeutics’ stock has dropped after it announced it was investigating the impact of a faulty batch of its investigational antibody therapy dosed in a Phase Ib/IIa trial.

PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.

At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in Barcelona, Spain, industry experts delivered comprehensive insights, examined ...

At the 2025 Congress of the European Hematology Association (EHA 2025), held from 12 to 15 June, the preliminary results from the global, multi-centre open-label non-randomised Phase II RedirecTT-1 ...

At the 24-week mark, 76% of them achieved a ≥75% improvement in overall disease severity, with some noticing benefits as early as two weeks. Additionally, 53% of patients saw a reduction in itch, and ...

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis (PsA) at 24 weeks in individuals, against a placebo in the randomised ...

Lundbeck’s humanised monoclonal antibody, Vyepti (eptinezumab), has met both primary and secondary endpoints in the placebo-controlled, randomised Phase IV RESOLUTION trial in patients with chronic ...

Last month, executives from biopharmaceutical companies, clinicians, and clinical trial experts in the field of oncology gathered at the 15th Annual Clinical Trial in Oncology West Coast (CTO) ...

Artificial intelligence (AI) has the potential to uncover valuable insights hidden in protocols and clinical study reports across the pharmaceutical industry, according to experts at the Outsourcing ...

In a recent webinar hosted by PCM Trials, regulatory, legal, and operational leaders came together to unpack the implications of this update and share strategies for proactive adaptation. Moderated by ...